|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
IGF-1 values were not predictive of GHD.
|
31661639 |
2020 |
|
Somatotropin deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression level of serum IGF-1 in GHD group was significantly lower than that in the control group (P<0.05).
|
30988753 |
2019 |
|
Somatotropin deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Nonspecific skeletal abnormalities were frequently noticed, and normal to elevated plasma IGF-I levels were observed in all except 1 patient with growth hormone deficiency.
|
31715605 |
2019 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
In a subgroup of patients with severe GHD, LVMi increased concomitantly to the decline in NT-proBNP and this was positively correlated to the final IGF-1 concentration.
|
31100717 |
2019 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
When implanted in rats with growth hormone deficiency and irradiated with an NIR light from the outside skin, the device exhibits profiles of hGH and IGF1 plasma concentrations, as well as body weight change, similar to those in animals treated with conventional s.c. hGH injections.
|
31123147 |
2019 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Growth hormone (GH) stimulation tests were performed 3-4 years post TBI in children with GH deficiency (GHD) 1 year post TBI and in all children with low height velocity (<-1 DS) or low IGF-1 (<-2 DS).
|
30884465 |
2019 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
The serum IGF-I concentration is commonly used as a screening tool for growth hormone deficiency (GHD), but there is no consensus on the cut-off limit of IGF-I standard deviation score (SDS) to perform GH stimulation tests for confirmation or exclusion of GHD.
|
31842524 |
2019 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
The diagnostic accuracy of GHRHarg testing and of IGF-I SDS in patients with GHD of different etiologies was evaluated by ROC analysis.
|
31417499 |
2019 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
After GHR, children with GHD showed a significant increase in height (P < 0.001), growth velocity (P < 0.001), IGF-I (P < 0.001), fasting glucose (P = 0.002) and insulin (P < 0.001), homeostasis model assessment estimate of insulin resistance (P < 0.001), and irisin (P = 0.005), with a concomitant decrease in BMI (P = 0.001) and WC (P = 0.003).
|
30418584 |
2019 |
|
Somatotropin deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Weekly dosing of somapacitan provided elevated IGF-I levels throughout the week, despite little or no accumulation of somapacitan, in both adults and children with GHD.
|
29671202 |
2019 |
|
Somatotropin deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The etiology of 104 children with short stature was classified according to the GH stimulation test and IGF-1 levels: (1) growth hormone deficiency (GHD); (2) mild growth hormone deficiency (M-GHD); (3) idiopathic short stature (ISS); (4) GH insensitivity syndrome (GHIS).
|
31301056 |
2019 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Baseline Insulin like growth factor binding protein 3 (IGFBP - 3) along with ∆ IGF - 1 in the first 3 months of GH therapy level can be a marker of growth response to the rGH and/or rIGF - 1 therapy in children with non - growth hormone deficiency short stature.
|
30197657 |
2018 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
We searched Medline, Embase, Cochrane Central Register of Controlled Trials and Database of Systematic Reviews, and Scopus for studies evaluating GHD that used IGF-1 or IGF-binding protein 3 (IGFBP-3) measurements compared with GH dynamic testing.
|
29982753 |
2018 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
AGHDA = Assessment of Growth Hormone Deficiency in Adulthood; CHOox = carbohydrate oxidation; ET = ejection time; fT3 = free triiodothyronine; fT4 = free thyroxine; GH = growth hormone; GHD = growth hormone deficiency; HB-RQ = high baseline respiratory quotient; HPT = hypothalamic-pituitary-thyroid; ICT = isovolumetric contraction time; IGF-1 = insulin-like growth factor 1; IRT = isovolumetric relaxation time; LB-RQ = low baseline respiratory quotient; LV = left ventricular; NHP = Nottingham Health Profile; QOL = quality of life; REE = resting energy expenditure; RQ = respiratory quotient; rT3 = reverse triiodothyronine; SF-36 = Short Form 36; TSH = thyroid-stimulating hormone; T3 = triiodothyronine; T4 = thyroxine; TT3 = total triiodothyronine; TT4 = total thyroxine.
|
29658834 |
2018 |
|
Somatotropin deficiency
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
No significant association of indices of growth hormone deficiency (IGF-1-level-SDS, years of unsubstituted growth hormone deficiency etc.) with telomere length was detected.
|
30352410 |
2018 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with IGHD - not cGHD - diagnosed during 2008-2015 (IV) were the youngest with most severe GHD (maxGH, IGF-I, IGFBP-3), and first year height velocity (HV) and ∆ IGF-I (10.5 cm/year, 4.0 SDS) but not ∆ height SDS were the highest on recombinant human growth hormone (rhGH) (27 μg/kg/day).
|
30332395 |
2018 |
|
Somatotropin deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Low IGF-1 levels despite normal weight/adequate nutrition were observed in six patients, suggesting growth hormone deficiency similar to PWS.
|
29496979 |
2018 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Impact of the Choice of IGF-I Assay and Normative Dataset on the Diagnosis and Treatment of Growth Hormone Deficiency in Children.
|
30286459 |
2018 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this study was to evaluate the reciprocal associations between bone formation markers [alkaline phosphatase (ALP), bone alkaline phosphatase (BALP)], the GH/IGF-1 axis and 25-hydroxyvitamin D [25(OH)D] in children with growth hormone deficiency at baseline and during recombinant human growth hormone (rhGH) therapy.
|
29649340 |
2018 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Predictive Value of Insulin-Like Growth Factor 1 in Irradiation-Dependent Growth Hormone Deficiency in Childhood Cancer Survivors.
|
30645996 |
2018 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Receiver operator curve analysis was performed to evaluate diagnostic threshold of IGF-1 z-score for determining GHD by GST or ITT.
|
29609574 |
2018 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
The results show that long-term GH treatment is associated with decreasing GH dose, increased IGF-I, decreased LDL-cholesterol and the presence of surrogate markers that help to give confidence in a diagnosis of GHD.
|
29536433 |
2018 |
|
Somatotropin deficiency
|
0.100 |
Biomarker
|
disease |
BEFREE |
Growth hormone deficiency (GHD) after TBI may impair axonal and neuropsychological recovery, and serum insulin-like growth factor-I (IGF-I) may mediate this effect.
|
28574152 |
2017 |
|
Somatotropin deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency.
|
27520559 |
2017 |
|
Somatotropin deficiency
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The presence of GHD and GH and IGF-1 levels were not predictive of relapses, new T2 lesions or conversion occurrence.
|
27982500 |
2017 |